Elena Basenach, Alisa Förster, Peter Raab, Samer Alzein, Gunnar Schmidt, Joachim K Krauss, Brigitte Schlegelberger, Fedor Heidenreich, Bernd Auber, Christian Hartmann, Bettina Wiese, Ruthild G Weber
Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by the growth of schwannomas, especially bilateral vestibular schwannomas (VS), meningiomas, and ependymomas. The anti-VEGF antibody bevacizumab has shown efficacy for VS in some NF2 patients. However, there is limited data on the effect of bevacizumab on non-vestibular tumors, and on the correlation between therapy response and genotype. Here, we report on a 33-year-old patient with bilateral VS, 14 additional intracranial or spinal schwannomas, and a meningioma treated with bevacizumab, off-label in the European Union, for 2 years...
July 2022: Clinical Neuropathology